Discontinued — last reported Q3 '19
Vertex Pharmaceuticals Lease Payments remained flat by 0.0% to $45.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.4%, from $28.38M to $45.80M. Over 2 years (FY 2023 to FY 2025), Lease Payments shows an upward trend with a 70.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Significant increases in cash payments without corresponding revenue growth may indicate tightening liquidity or rising fixed cost commitments.
This metric represents the actual cash outflow associated with operating lease liabilities during the period. It is a ke...
Reported in the 'Supplemental Cash Flow Information' section of the lease disclosures.
is_cvx_operating_lease_payments_cash| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $62.80M | $113.50M | $183.20M |
| YoY Change | — | +80.7% | +61.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.